OpenDNA Overview
OpenDNA is developing an AI platform that combines clinical and genomic data analysis for polygenic diseases. The platform allows healthcare providers and payers to easily apply genomic precision medicine and population genomics approaches. Its prediction models help identify high risk patients and their key (or targeted) prevention strategies. The company has already implemented its AI solutions for cardiometabolic syndrome, and in the future means to apply the technology to other complex polygenic disease states, such as cancer; chronic kidney failure; and autoimmune, neurological, and musculoskeletal diseases.
Cumulative Funding Raised Over Time ($)
$700KJun 2020
$700KMar 2022
$1.7MMar 2023
Latest News
growth-positive
OpenDNA Partners with PartnerMD to Provide Patients with AI-Based Genetic Risk Testing for Cardiometabolic diseases
OpenDNA, a provider of precision medicine AI solutions, has formed a commercial partnership with PartnerMD, a leader in concierge health and wellness. PartnerMD will offer its patients OpenDNA’s CardioRisk+ AI-based genetic tests to provide individual risk insights that help improve patient care and create preventive management strategies. OpenDNA’s CardioRisk+ is a comprehensive genetic test that uses AI to analyze over 6 million SNPs as well as an extensive number of clinical biomarkers associated with cardiovascular disease, hypertension, diabetes, and hypercholesterolemia.
PartnersCustomers
growth-positive
OpenDNA Announces Successful Conclusion of 150 Patient Clinical Study
OpenDNA, a provider of precision medicine AI solutions, has announced the successful completion of a clinical study evaluating its AI platform for predicting cardiovascular disease (CVD) risk. The study was conducted in three clinics in Maryland and New Jersey, enrolling 150 patients with various risk factors. The platform, based on a deep learning algorithm trained on a large dataset of genetic and clinical data, is currently being used by clinicians in the United States, Europe, and Israel. OpenDNA plans to continue developing its platform and expand its clinical trials.
CustomersExpand
growth-positive
סטטוסקופ חכם ואבחון מחלות באמצעות "אההה": 8 פיתוחים ישראליים חדשים ברפואה דיגיטלית | גיקטיים
Startup City Haifa, a digital health accelerator, has seen eight promising startups graduate from its latest cycle. The accelerator, which began in June, selected the eight companies from 120 applicants. The startups are working on a range of innovative solutions, including identifying signs of mental distress through mobile phones, preventing loss cases, identifying strokes and heart diseases through phone calls, and creating dramatic improvements in vision through image processing in the brain. The program is led by JVP, Road2, NVIDIA Incept, Margalit Startup City, and the Innovation Authority in partnership with Super-Pharm, Clalit Health Services, IBM, Philips, U-BANK, Technion, University of Haifa, and others.
PartnersCustomers
growth-positive
OpenDNA announces know-how and research agreement with Mayo Clinic as part of pilot clinical study for cardiovascular disease prevention
OpenDNA has entered into a know-how and research agreement with Mayo Clinic for a pilot clinical study to evaluate OpenDNAs technology for early risk prediction of cardiovascular disease. OpenDNAs AI platform will analyze genetic and clinical data to predict a patients risk for developing cardiovascular disease. The collaboration aims to bring forth a new precision medicine approach to predict and treat complex polygenic diseases. OpenDNA has completed validation studies showing 85% accuracy in predicting heart attacks. Mayo Clinic has a financial interest in the technology and will use any revenue to support its not-for-profit mission.
Partners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $2.45M |
| Last funding | $250K |
| Stage | Seed |
| Rounds | 5 |
| Investors | 3 |
Team Members
3
Employees: 1-10
Web & Social Links
| Website | www.open-dna.com |
Locations
Netiv HaOr 1, Haifa, Israel
Photos & Videos
1 item(s)
OpenDNA Business
Business models
B2B
Product stage
Clinical Trial
Employees
1-10
Sector
Health Tech & Life SciencesDigital HealthcareMedical Decision SupportTarget Customer
Healthcare & Life SciencesHealthcareProvidersInsurance CompaniesCore Technology
BiologicalsGenesArtificial IntelligenceMachine LearningTags (13)
blood-pressurechronic-diseasehealthcare-providerscardiovasculardigital-healthcareartificial-intelligencepatientsheart-diseasespersonalized-medicinemhealthdiabetesgeneticsheart-failureGeographic Markets
United StatesEuropeOpenDNA Financials
$2.45M
Total funding
Undisclosed
Capital raised
$250K
Last funding
Seed
Funding stage
5
Total rounds
3
Investors
Cumulative Funding Raised Over Time ($)
$700KJun 2020
$700KMar 2022
$1.7MMar 2023
Private Equity Funding
SAFE
Mar 2023
$1M
Equity crowdfunding
Mar 2022
Undisclosed
ExitValley (Lead)
Seed
Jun 2020
$700K
MindUP, Israel Innovation Authority
Non-Equity Funding
GrantEvent
Oct 2023
$250K
GrantEvent
Mar 2023
$500K
OpenDNA Lifecycle
Cumulative Funding Raised Over Time
$700KJun 2020
$700KMar 2022
$1.7MMar 2023
All Events
SAFE
Mar 2023
$1M
Equity crowdfunding
Mar 2022
Undisclosed
ExitValley (Lead)
Seed
Jun 2020
$700K
MindUP, Israel Innovation Authority
GrantEvent
Oct 2023
$250K
GrantEvent
Mar 2023
$500K
OpenDNA News
4 articles
growth-positive
OpenDNA Partners with PartnerMD to Provide Patients with AI-Based Genetic Risk Testing for Cardiometabolic diseases
OpenDNA, a provider of precision medicine AI solutions, has formed a commercial partnership with PartnerMD, a leader in concierge health and wellness. PartnerMD will offer its patients OpenDNA’s CardioRisk+ AI-based genetic tests to provide individual risk insights that help improve patient care and create preventive management strategies. OpenDNA’s CardioRisk+ is a comprehensive genetic test that uses AI to analyze over 6 million SNPs as well as an extensive number of clinical biomarkers associated with cardiovascular disease, hypertension, diabetes, and hypercholesterolemia.
PartnersCustomers
growth-positive
OpenDNA Announces Successful Conclusion of 150 Patient Clinical Study
OpenDNA, a provider of precision medicine AI solutions, has announced the successful completion of a clinical study evaluating its AI platform for predicting cardiovascular disease (CVD) risk. The study was conducted in three clinics in Maryland and New Jersey, enrolling 150 patients with various risk factors. The platform, based on a deep learning algorithm trained on a large dataset of genetic and clinical data, is currently being used by clinicians in the United States, Europe, and Israel. OpenDNA plans to continue developing its platform and expand its clinical trials.
CustomersExpand
growth-positive
סטטוסקופ חכם ואבחון מחלות באמצעות "אההה": 8 פיתוחים ישראליים חדשים ברפואה דיגיטלית | גיקטיים
Startup City Haifa, a digital health accelerator, has seen eight promising startups graduate from its latest cycle. The accelerator, which began in June, selected the eight companies from 120 applicants. The startups are working on a range of innovative solutions, including identifying signs of mental distress through mobile phones, preventing loss cases, identifying strokes and heart diseases through phone calls, and creating dramatic improvements in vision through image processing in the brain. The program is led by JVP, Road2, NVIDIA Incept, Margalit Startup City, and the Innovation Authority in partnership with Super-Pharm, Clalit Health Services, IBM, Philips, U-BANK, Technion, University of Haifa, and others.
PartnersCustomers
growth-positive
OpenDNA announces know-how and research agreement with Mayo Clinic as part of pilot clinical study for cardiovascular disease prevention
OpenDNA has entered into a know-how and research agreement with Mayo Clinic for a pilot clinical study to evaluate OpenDNAs technology for early risk prediction of cardiovascular disease. OpenDNAs AI platform will analyze genetic and clinical data to predict a patients risk for developing cardiovascular disease. The collaboration aims to bring forth a new precision medicine approach to predict and treat complex polygenic diseases. OpenDNA has completed validation studies showing 85% accuracy in predicting heart attacks. Mayo Clinic has a financial interest in the technology and will use any revenue to support its not-for-profit mission.
Partners
OpenDNA Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 7 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 11 classification IDs that could be used for matching.
OpenDNA Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 98/100 |
| Missing | markets |
| BI Verification | Yotam Maman |
| Registrar ID | 515903276 |
| Creator | Yotam Maman |
| Creator email | yotamm1988@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-01-19T00:00:00.000Z |
| Created | 2020-08-20T00:00:00.000Z |
| Claimed | Yes |